Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating Safety and Efficacy of Ublituximab in Participants With Schizophrenia

NCT07680946 is registered in ClinicalTrials.gov with TG Therapeutics, Inc. as lead sponsor.

NCT NCT07680946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07680946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating Safety and Efficacy of Ublituximab in Participants With Schizophrenia
Lead sponsor
TG Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
July 27, 2026
Completion date
March 1, 2029
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia